News Release

August 22nd, 2016
PeptiDream Inc
http://www.peptidream.com/
(Ticker Code：4587 TSE First Section)

Tokyo Institute of Technology

PeptiDream Announces Collaboration for In Silico Constrained Peptide Drug Discovery and Development

TOKYO, JAPAN – August 22nd, 2016 – PeptiDream Inc., a public Tokyo-based biopharmaceutical company ("PeptiDream")(Tokyo:4587) announced today that it has entered into a collaboration with the Tokyo Institute of Technology ("Tokyo Tech") for the in silico discovery and development of constrained peptides using Tokyo Tech's TSUBAME 2.5 supercomputer and related technologies.

PeptiDream has generated and continues to generate a significant amount of information and learnings regarding the discovery and development of the company's constrained peptides as therapeutics, attained across PeptiDream's extensive collaboration partners and internal company programs. These critical learnings have significantly advanced PeptiDream's understanding of the therapeutic properties of constrained peptides, such as the effect of peptide solubility, plasma stability, metabolic stability, plasma protein binding, 2D/3D structure, etc., on the pharmacokinetic and pharmacologic activity of these molecules. PeptiDream has been looking to more systematically and comprehensively leverage these learnings to more efficiently optimize and accelerate the discovery and development of peptide therapeutics. In this collaboration, PeptiDream will provide Tokyo Tech with various experimental data related to these molecules, to which Tokyo Tech will generate powerful in silico prediction and simulation computational technologies that promise to significantly accelerate the optimization and development of peptide candidates identified from PeptiDream's PDPS technology.

**Professor Yutaka Akiyama (also concurrent Professor, Smart Drug Discovery Research Unit, Information Science and Technology Institute) at the Tokyo Institute of Technology is one of the world leaders in in silico molecular simulation and prediction technologies using supercomputing.

[Comment from Patrick Reid SVP and Keiichi Masuya VP of PeptiDream Inc]

"We are very excited about initiating this collaboration with Tokyo Tech, one of the world-leaders in applying supercomputing to in silico drug discovery and development. The essence of this collaboration will be to combine PeptiDream's extensive knowledge of constrained peptide therapeutics with Tokyo Tech's extensive expertise in in silico molecule simulation and prediction methodologies and technologies to better predict, design, discover, and development better constrained peptide therapeutics."

Over the past six years, PeptiDream has established funded discovery collaborations with 16 leading pharmaceutical companies; Amgen, AstraZeneca, Bristol-Myers Squibb, Lilly, GlaxoSmithKline, Novartis, Mitsubishi Tanabe, Daiichi Sankyo, Merck, Sanofi, Teijin, Kyorin, Ipsen, Genentech, Shionogi, and Asahi Kasei Pharma all of which are active and ongoing. In addition, PeptiDream has transferred its PDPS discovery platform for broad use to Bristol-Myers-Squibb, Novartis, Lilly and Genentech.

<About PeptiDream Inc.>
PeptiDream Inc. is a public (Tokyo Stock Exchange 1st Section 4587) biopharmaceutical company founded in 2006 employing our proprietary Peptide Discovery Platform System (PDPS), a state-of-the-art highly versatile discovery platform which enables the production of highly diverse (trillions) non-standard peptide libraries with high efficiency, for the identification of highly potent and selective hit candidates, which then can be developed into peptide-based or small molecule-based therapeutics. PeptiDream aspires to be a world leader in drug discovery and development to address unmet medical needs and improve the quality of life of patients worldwide. For further information, please visit mwww.peptidrea.com

< About Tokyo Institute of Technology >
Tokyo Institute of Technology stands at the forefront of research and higher education as the leading university for science and technology in Japan. Tokyo Tech researchers excel in a variety of fields, such as material science, biology, computer science and physics. Founded in 1881, Tokyo Tech has grown to host 10,000 undergraduate and graduate students who become principled leaders of their fields and some of the most sought-after scientists and engineers at top companies. Embodying the Japanese philosophy of "monotsukuri," meaning technical ingenuity and innovation, the Tokyo Tech community strives to make significant contributions to society through high-impact research. Website:www.titech.ac.jp/english/index

Enquiries:
PeptiDream Inc.
Patrick C Reid +81-3-3468-9022 (Tokyo)
EMAIL: p-reid@peptidream.com

Tokyo Institute of Technology
Center for Public Affairs and Communications
+81-3-5734-2975(Tokyo)
EMAIL: media@jim.titech.ac.jp